Next Article in Journal
History of Newborn Screening for Cystic Fibrosis—The Early Years
Previous Article in Journal
Measurement of 17-Hydroxyprogesterone by LCMSMS Improves Newborn Screening for CAH Due to 21-Hydroxylase Deficiency in New Zealand
Open AccessCommunication

Clinical Utility of Confirmatory Genetic Testing to Differentiate Sickle Cell Trait from Sickle-β+-Thalassemia by Newborn Screening

by 1,2,3,*, 1,2 and 1,2,3,4
1
Ohio Department of Health Regional Sickle Cell Services Program–Region 1, Cincinnati, OH 45229, USA
2
Cincinnati Comprehensive Sickle Cell Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
3
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
4
Erythrocyte Diagnostic Laboratory, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2020, 6(1), 7; https://doi.org/10.3390/ijns6010007
Received: 14 October 2019 / Revised: 15 January 2020 / Accepted: 28 January 2020 / Published: 31 January 2020
Hemoglobin separation techniques are the most commonly used laboratory methods in newborn screening and confirmatory testing programs for hemoglobinopathies. However, such protein-based testing cannot accurately detect several hemoglobinopathies in newborns, especially when β-thalassemia mutations are involved. Here, we describe a consecutive cohort of newborns who were identified by newborn screening to have a likely diagnosis of sickle-β+-thalassemia (having an “FSA” pattern) who were determined to have sickle cell traits by confirmatory and genetic testing. We illustrate the clinical utility of genetic testing to make a correct and timely diagnosis in the setting of newborn screening for hemoglobinopathies. View Full-Text
Keywords: genetic testing; sickle cell trait; sickle cell disease; sickle-β+-thalassemia; newborn screening for hemoglobinopathies genetic testing; sickle cell trait; sickle cell disease; sickle-β+-thalassemia; newborn screening for hemoglobinopathies
Show Figures

Figure 1

MDPI and ACS Style

Shook, L.M.; Haygood, D.; Quinn, C.T. Clinical Utility of Confirmatory Genetic Testing to Differentiate Sickle Cell Trait from Sickle-β+-Thalassemia by Newborn Screening. Int. J. Neonatal Screen. 2020, 6, 7. https://doi.org/10.3390/ijns6010007

AMA Style

Shook LM, Haygood D, Quinn CT. Clinical Utility of Confirmatory Genetic Testing to Differentiate Sickle Cell Trait from Sickle-β+-Thalassemia by Newborn Screening. International Journal of Neonatal Screening. 2020; 6(1):7. https://doi.org/10.3390/ijns6010007

Chicago/Turabian Style

Shook, Lisa M.; Haygood, Deidra; Quinn, Charles T. 2020. "Clinical Utility of Confirmatory Genetic Testing to Differentiate Sickle Cell Trait from Sickle-β+-Thalassemia by Newborn Screening" Int. J. Neonatal Screen. 6, no. 1: 7. https://doi.org/10.3390/ijns6010007

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop